Behind Jiahe bio's a share: only one new three board plant extract concept share lost money

July 7 news, a few days ago, Jiahe biology, an innovative company in the new third board, announced that it wanted to break through the A-share market and go public in China According to the statistical data of dig Beiwang, only one company in the new three board plant extract industry made a loss last year The overall profitability of the industry is strong, and Jiahe biology ranks first in the industry Jiahe biology wants to double the profits of a shares in the past three years On October 20, 2015, Jiahe biology officially listed on the new third board The company is mainly engaged in the research and development, production and sales of natural plant extracts and natural pharmaceutical intermediates At present, the main products are shikimic acid, resveratrol, 5-hydroxytryptophan, silymarin extract, red axle extract, Epimedium extract, etc It is understood that Jiahe biological customers are mainly pharmaceutical, health care, dietary supplements, cosmetics, beverage and food production enterprises, and the company's products are mainly exported In terms of financial data, Jiahe biological's business performance in recent three years has continued to rise During the three years from 2014 to 2016, Jiahe biology achieved operating revenue of 511 million yuan, 619 million yuan and 665 million yuan respectively, and net profit of 35695800 yuan, 44723100 yuan and 76735700 yuan In 2016, corporate profits doubled compared with 2014 Public information shows that Jiahe bio has successfully completed two rounds of financing since its listing, raising a total of 136 million Nearly two years after listing, Jiahe biology has entered the stage of listing guidance, and is currently receiving guidance from Western securities Only one enterprise in the new three board concept unit of plant extracts lost money According to the data of the new three board Research Institute, as of July 7, 2017, 20 new three board concept units of plant extracts have officially landed on the new three board In 2016, the industry's overall profitability was strong, with 20 plant extract enterprises achieving a net profit of 183 million yuan last year; the overall operating performance of last year increased by 15 million yuan compared with the total net profit of 168 million yuan in 2015 Among them, 19 enterprises made profits, only one lost, and the net profit of 5 enterprises was negative growth It is worth noting that the company achieved a revenue of 15.7919 million yuan and a performance loss of 54.3167 million yuan last year In 2016, compared with 2015, it changed from profit to loss Among the above 20 new third board enterprises, 7 enterprises, including Tiancao Biology (835644) and Tiansheng Pharmaceutical (836140), have a net profit of 10-30 million yuan, while 9 enterprises, including Oukang Pharmaceutical (833230) and Ningbo traditional Chinese medicine (833528), have achieved profits, but their net profits are all less than 10 million yuan According to the data statistics of the new third board Research Institute of digsbei.com, Jiahe biological profitability is the first in the whole industry Net profit in 2016 increased by 72% year on year.